Tag
Continuing antidepressants in pregnancy lowers postpartum depression risk irrespective of race or ethnicity; prenatal depressive symptoms severity is critical for personalized treatment.
A large-scale retrospective cohort study identifies specific phenotypic traits and genetic markers, including the SLAMF3/LY9 locus, that predict antidepressant treatment complexity and sustained use, offering a roadmap for precision psychia
A landmark network meta-analysis demonstrates that slow antidepressant tapering (>4 weeks) combined with psychological support is as effective as drug continuation in preventing relapse, providing a safe, evidence-based pathway for patie
A 151‑trial network meta‑analysis of 58,534 participants shows marked differences among 30 antidepressants in weight, blood pressure, heart rate, lipids, glucose and liver enzymes; findings support individualized choice and targeted baselin
A propensity score analysis of STEP-BD data reveals no significant association between antidepressant use and either manic switch risk or symptomatic remission in bipolar depression, highlighting the need for alternative treatment strategie
This review synthesizes evidence linking long-term air pollution and road traffic noise exposure with antidepressant medication dispensing, highlighting sex-specific associations and implications for mental health prevention strategies.
An FDA expert panel debates the risks and benefits of SSRI antidepressants in pregnancy, emphasizing the need to weigh untreated depression risks against potential drug-related fetal outcomes.
A new FDA panel reignites debate over the safety and efficacy of antidepressant use during pregnancy, with experts weighing in on emerging research and practice recommendations.
